CAS: 56026-36-9; Methyl 6-(Hydroxymethyl)Nicotinate

相似化合物

10165-86-3 17874-79-2 881-86-7

上下游产品

dimethyl 2,5-pyridine dicarboxylate methyl 6-(N-methoxy-N-methylcarbamoyl)pyridine-3-carboxylate methyl 6-(acetoxymethyl)nicotinate Pyridine-2,5-dicarboxylic acidN-(3-aminopropyl)-6-hydroxymethylnicotinamide methyl 6-formylpyridine-3-carboxylate 6-(hydroxymethyl)pyridine-3-carboxylic acid 6-(5'-methoxycarbonyl-2'-pyridyl)-3-phenyl-1,2,4-triazine

5-(Methoxycarbonyl)-2-Methylpyridine 1-Oxide置于三氟乙酸酐体系中,用 二氯甲烷 作为反应溶剂,化学反应 2.0H,以58%的收率获得产物6-羟甲基烟酸甲酯
参考文献: Btk Inhibitors[fr] Inhibiteurs De Btk
标题: Btk Inhibitors[fr] Inhibiteurs De Btk
摘要:根据公式i提供了bruton'S酪氨酸激酶(btk)抑制剂化合物,或其药学上可接受的盐,或包含这些化合物的药物组合物,并且这些化合物在治疗中的用途.特别提供了使用公式i的btk抑制剂化合物来治疗btk介导的疾病.

专利信息

专利号:US-7842813-B2
优先权日:2008-05-09
标 题 :Processes for the preparation of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine
发明人：TANG DATONG; HAN YINGLIN; HUANG YANHE; PHAN LY TAM; OR YAT SUN; WANG ZHE
权利人:ENANTA PHARM INC
摘要:The present invention relates generally to novel methods for the synthesis of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts in PCT Application WO 03/097659 A1. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (Ia):